Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)Business Wire • 03/16/23
This HealthCare Company Is Gearing Up for Its Next Launch: Here Is Why The Stock Is a BuyThe Motley Fool • 03/10/23
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 DiabetesBusiness Wire • 03/09/23
Vertex Pharmaceuticals Incorporated (VRTX) 43rd Annual Cowen Healthcare Conference TranscriptSeeking Alpha • 03/08/23
Nasdaq Bear Market: 5 Superb Growth Stocks You'll Regret Not Buying on the DipThe Motley Fool • 02/25/23